A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05275673. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label Phase 2 Study of the TORC 1/2 Inhibitor Sapanisertib in Relapsed/Refractory NFE2L2 (NRF2)-Mutated and Wild-Type (WT) Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Study identification
- NCT ID
- NCT05275673
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Faeth Therapeutics
- Industry
- Enrollment
- 7 participants
Conditions and interventions
Conditions
Interventions
- sapanisertib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 20, 2022
- Primary completion
- Jan 23, 2023
- Completion
- Jan 23, 2023
- Last update posted
- Apr 23, 2025
2022 – 2023
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Davis Comprehensive Cancer Center | Davis | California | 95817 | — |
| Providence Medical Group Santa Rosa - Cancer Center | Santa Rosa | California | 95403 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Ocala Oncology Center | Ocala | Florida | 34474 | — |
| Florida Cancer Specialists | Tallahassee | Florida | 32308 | — |
| Norton Cancer Institute, Downtown | Louisville | Kentucky | 40202 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University - Patient Care Coordinator Center | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center - Thoracic | New York | New York | 10065 | — |
| Zangmeister Cancer Center | Columbus | Ohio | 43219 | — |
| Providence Cancer Institute Franz Clinic | Portland | Oregon | 97213 | — |
| UPMC Cancer Pavilion | Pittsburgh | Pennsylvania | 15232 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Virginia Cancer Specialist, PC | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05275673, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2025 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05275673 live on ClinicalTrials.gov.